The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …

Background The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-
generation, highly selective oral Bruton's tyrosine kinase inhibitor, were evaluated for …

PURPOSE Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase
(BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase …

Atrial fibrillation (AF) has been reported in up to 16% of patients taking ibrutinib. Data
regarding the management of AF in this patient population are limited, and stroke prevention …

Introduction: Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-
cell lymphomas. Zanubrutinib was designed to achieve improved therapeutic concentrations …

HER4 is a receptor tyrosine kinase that is required for the evolution of normal body systems
such as cardiovascular, nervous, and endocrine systems, especially the mammary glands. It …

Drug–target interaction (DTI) prediction plays an important role in drug repositioning, drug
discovery and drug design. However, due to the large size of the chemical and genomic …

Ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL). This drug
irreversibly inhibits Bruton tyrosine kinase (BTK) by covalently binding to the C481 residue …